SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Historical Holders from Q1 2014 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: SGMO on Nasdaq
Shares outstanding: 294,683,714
Price per share: $0.42
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 62,599,661
Total reported value: $42,142,133
% of total 13F portfolios: 0%
Share change: -10,625,760
Value change: -$4,085,111
Avg buy value change: +0%
Avg sell value change: -0%
Number of holders: 111
Price from insider filings: $0.4166

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
WASATCH ADVISORS LP	2.1%	-62%	$4,167,240	-$3,664,854	6,188,358	-47%	Wasatch Advisors LP	30 Sep 2025

As of 30 Sep 2025, SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 111 institutional shareholders filing 13F forms. They hold 62,599,661 shares. of 294,683,714 outstanding shares (21%) .

Top 25 institutional shareholders own 19% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
VANGUARD GROUP INC	3.9%	11,615,150	+24%	0%	$7,816,996
RENAISSANCE TECHNOLOGIES LLC	3.5%	10,182,463	+49%	0.01%	$6,856,871
BlackRock, Inc.	1.5%	4,556,208	-5.3%	0%	$3,068,150
GSA CAPITAL PARTNERS LLP	1.2%	3,662,478	+63%	0.21%	$2,466,000
GEODE CAPITAL MANAGEMENT, LLC	1.1%	3,286,476	+41%	0%	$2,213,762
TWO SIGMA INVESTMENTS, LP	0.84%	2,479,186	+183%	0%	$1,669,484
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.82%	2,420,366	+213%	0%	$1,629,874
JANE STREET GROUP, LLC	0.75%	2,200,685		0%	$1,481,942
TWO SIGMA ADVISERS, LP	0.72%	2,108,355	+75%	0%	$1,419,766
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.52%	1,538,998	+20%	0%	$1,036,361
WASATCH ADVISORS LP	0.48%	1,426,453	-82%	0.01%	$960,573
STATE STREET CORP	0.46%	1,355,583	+62%	0%	$912,850
UBS Group AG	0.45%	1,320,818	+5.7%	0%	$888,911
Ikarian Capital, LLC	0.44%	1,294,652	+2.7%	0.2%	$871,819
CITADEL ADVISORS LLC	0.41%	1,208,415	+519%	0%	$813,747
ORACLE INVESTMENT MANAGEMENT INC	0.34%	1,004,724		0.47%	$676,581
JACOBS LEVY EQUITY MANAGEMENT, INC	0.29%	846,533	0%	0%	$570,055
Invesco Ltd.	0.27%	808,731	+19%	0%	$544,599
HighTower Advisors, LLC	0.25%	744,106	-0.09%	0%	$501,081
NORTHERN TRUST CORP	0.22%	639,680	+61%	0%	$430,761
MORGAN STANLEY	0.2%	592,153	+3.4%	0%	$398,756
ROYAL BANK OF CANADA	0.18%	523,745	+0.66%	0%	$352,000
GROUP ONE TRADING LLC	0.17%	502,004	+116%	0.01%	$338,049
GOLDMAN SACHS GROUP INC	0.15%	446,854	+145%	0%	$300,911
Golden State Equity Partners	0.14%	418,943	+6.9%	0.05%	$282,116

Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	80,133	$34,748	-$209,495			$0.42	3
2025 Q3	62,599,661	$42,142,133	-$4,085,111	$742,471	$643,403	$0.67	111
2025 Q2	73,226,422	$39,627,130	-$1,366,573	$426,288	$596,648	$0.54	111
2025 Q1	52,557,554	$34,474,526	-$6,973,706	$1,205,290	$1,447,309	$0.66	118
2024 Q4	61,545,399	$62,815,026	+$5,838,247	$1,822,842	$1,397,910	$1.02	125
2024 Q3	55,892,914	$48,377,748	-$13,237,486	$1,014,241	$500,291	$0.87	101
2024 Q2	86,879,403	$31,098,479	-$5,527,369	$55,892	$12,857	$0.36	126
2024 Q1	100,428,408	$67,260,619	+$9,872,665	$44,099	$23,789	$0.67	127
2023 Q4	75,056	$42,895	-$20,037			$0.57	2
2023 Q3	102,140,618	$61,237,233	-$4,209,968	$59,380	$48,467	$0.60	129
2023 Q2	105,231,030	$136,414,962	-$10,630,007	$56,810	$74,360	$1.30	147
2023 Q1	110,036,513	$193,582,851	+$11,776,789	$74,976	$193,872	$1.76	173
2022 Q4	103,425,242	$324,314,250	+$18,086,507	$428,924	$1,001,618	$3.14	174
2022 Q3	91,195,414	$447,032,553	+$40,107,044	$1,417,000	$2,059,030	$4.90	181
2022 Q2	88,895,147	$367,823,719	+$45,571,302	$1,143,000	$2,150,000	$4.14	172
2022 Q1	77,718,533	$452,055,243	+$17,430,907	$1,875,000	$2,989,000	$5.81	177
2021 Q4	75,544,610	$566,818,839	+$12,734,558	$4,667,000	$4,952,000	$7.50	175
2021 Q3	75,237,286	$679,001,327	-$11,358,104	$6,094,000	$7,226,000	$9.01	186
2021 Q2	76,161,695	$911,518,870	-$39,762,540	$9,201,000	$10,356,000	$11.97	191
2021 Q1	79,088,392	$990,804,060	+$8,421,820	$11,227,000	$15,111,000	$12.53	192
2020 Q4	77,987,397	$1,217,240,331	-$2,066,292	$18,646,000	$34,532,000	$15.60	211
2020 Q3	81,520,171	$771,171,124	+$42,841,455	$9,509,000	$11,510,000	$9.45	199
2020 Q2	77,018,695	$689,879,920	+$38,548,916	$8,298,000	$10,948,000	$8.96	193
2020 Q1	73,964,031	$471,171,732	-$44,061,081	$5,092,000	$6,329,000	$6.37	171
2019 Q4	78,436,609	$656,385,766	-$35,455,503	$11,337,000	$5,147,000	$8.37	183
2019 Q3	82,072,134	$743,640,322	+$18,180,862	$10,336,000	$11,809,000	$9.05	175
2019 Q2	79,837,082	$859,762,341	+$188,070,689	$13,917,000	$21,130,000	$10.77	174
2019 Q1	62,185,655	$593,239,662	+$8,476,210	$12,941,000	$17,750,000	$9.54	173
2018 Q4	63,910,787	$733,496,400	-$24,446,398	$18,072,000	$16,092,000	$11.48	185
2018 Q3	63,304,478	$1,073,039,835	+$5,358,869	$25,972,000	$29,563,000	$16.95	211
2018 Q2	64,651,762	$918,038,586	+$101,748,037	$22,885,000	$22,129,000	$14.20	204
2018 Q1	57,191,865	$1,086,683,045	+$32,047,220	$20,663,000	$16,471,000	$19.00	205
2017 Q4	55,530,240	$910,720,543	+$36,691,608	$16,249,000	$22,039,000	$16.40	165
2017 Q3	54,652,539	$819,732,570	+$37,422,011	$10,299,000	$12,510,000	$15.00	147
2017 Q2	53,038,835	$466,764,979	+$100,982,648	$7,030,000	$7,834,000	$8.80	143
2017 Q1	41,839,242	$217,547,271	+$36,387,773	$1,672,000	$1,561,000	$5.20	113
2016 Q4	41,038,303	$125,153,665	-$11,920,369	$612,000	$977,000	$3.05	119
2016 Q3	43,619,818	$201,948,438	-$12,326,820	$793,000	$2,078,000	$4.63	119
2016 Q2	46,220,859	$267,610,930	-$15,551,476	$748,000	$1,794,000	$5.79	136
2016 Q1	48,689,102	$292,361,107	-$3,975,822	$664,000	$1,647,000	$6.05	141
2015 Q4	48,785,042	$445,425,385	-$33,232,334	$1,937,000	$24,798,000	$9.13	137
2015 Q3	51,223,916	$288,891,899	-$28,410,288	$1,859,000	$15,409,000	$5.64	141
2015 Q2	49,619,716	$550,188,135	-$34,256,205	$2,842,000	$128,398,000	$11.09	154
2015 Q1	50,986,486	$799,217,264	+$55,391,133	$6,844,000	$86,406,000	$15.68	165
2014 Q4	46,355,458	$704,672,239	-$10,978,103	$5,569,000	$98,439,000	$15.21	157
2014 Q3	48,505,425	$523,162,567	+$6,234,502	$4,017,000	$134,220,000	$10.78	154
2014 Q2	46,057,308	$703,163,055	+$28,857,869	$5,969,000	$87,658,000	$15.27	151
2014 Q1	48,194,025	$871,048,782	+$75,341,835	$19,469,000	$224,158,000	$18.08	143